Research graph
References from Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Immuno-oncology therapy in metastatic bladder cancer: a systematic review and network meta-analysis
10.1016/j.critrevonc.2021.103534 · 2022 · External reference
From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma
10.1016/j.euo.2018.05.011 · 2018 · External reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · 2024 · External reference
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986
10.1200/jco.2011.37.3571 · 2012 · External reference
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study
10.1200/jco.1992.10.7.1066 · 1992 · External reference
Genomic characterization of upper tract urothelial carcinoma
10.1016/j.eururo.2015.07.039 · 2015 · External reference
Prognostic effect of FGFR mutations or gene fusions in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: results from a large, single-institution cohort
10.1016/j.euf.2018.02.013 · 2019 · External reference
A place for precision medicine in bladder cancer: targeting the FGFRs
10.2217/fon-2016-0042 · 2016 · External reference
Erdafitinib in locally advanced or metastatic urothelial carcinoma
10.1056/nejmoa1817323 · 2019 · External reference
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
10.1016/s1470-2045(21)00660-4 · 2022 · External reference
Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma
10.1056/nejmoa2308849 · 2023 · External reference
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
10.1016/j.annonc.2023.10.003 · 2024 · External reference
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
10.1016/j.annonc.2024.03.001 · 2024 · External reference
European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines
10.1016/j.eururo.2025.02.019 · 2025 · External reference
The genomic and transcriptomic landscape of metastastic urothelial cancer
10.1038/s41467-024-52915-0 · 2024 · External reference
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer
10.1038/s41467-026-69927-7 · 2026 · External reference
